Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Plos One|November 27, 2014
Uncertainty and denial: a resource-rational model of the value of informationEmma Pierson, Noah GoodmanPlos One|June 13, 2019
Cake or broccoli? Recency biases children's verbal responsesEmily Sumner, Erika DeAngelis, Mara Hyatt, et al.Cognitive Science|January 29, 2014
One and done? Optimal decisions from very few samplesEdward Vul, Noah Goodman, Thomas L Griffiths, et al.Developmental Science|February 26, 2013
The mentalistic basis of core social cognition: experiments in preverbal infants and a computational modelJ Kiley Hamlin, Tomer Ullman, Josh Tenenbaum, et al.Critical Care Medicine|October 1, 2009
No assisted ventilation cardiopulmonary resuscitation and 24-hour neurological outcomes in a porcine model of cardiac arrestDemetris Yannopoulos, Timothy Matsuura, Scott McKnite, et al.JAMA Oncology|January 1, 2016
Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune MonitoringJashodeep Datta, Megan Fracol, Matthew T McMillan, et al.Kidney International|August 26, 2004
Duffy antigen receptor and genetic susceptibility of African Americans to acute rejection and delayed functionKevin C Mange, Eline Luning Prak, Malek Kamoun, et al.Breast Cancer Research : BCR|May 23, 2015
Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancerJashodeep Datta, Erik Berk, Shuwen Xu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancerDiane Lauren Reidy, Efsevia Vakiani, Marwan G Fakih, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2014
CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessmentAngela DeMichele, Amy S Clark, Kay See Tan, et al.Pageof 2